Eyam Health and iiDiagnostics have embarked on a groundbreaking collaboration to enhance vaccine development through advanced technology. This partnership aims to integrate Eyam’s innovative vaccine design and delivery systems with the cutting-edge automated organoid models developed by the Liverpool School of Tropical Medicine (LSTM). This initiative, which boasts a funding of £750,000, represents a significant step forward in the battle against infectious diseases.
Funding and Support
The project has secured substantial financial backing from various sources, including advisory services and funding amounting to CAD 455,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). This support is part of a larger funding pool that includes contributions from Innovate UK and iiDiagnostics. With these resources, the collaboration is well-positioned to advance research and development in vaccine technology.
Pioneering Research Facilities
The research will take place within the Liverpool Robotic Infection Research Laboratory, a state-of-the-art facility designed to handle high-risk infectious diseases. This laboratory is distinguished as one of the first Category Three Level robotic laboratories in the UK, equipped with sophisticated liquid handling systems and robotic analytical equipment. This environment will enable researchers to conduct experiments safely and efficiently, a crucial aspect when dealing with infectious threats.
Advanced Vaccine Platforms
At the heart of this collaboration is the development of a novel tonsillar organoid model, which will facilitate high-fidelity testing of Eyam’s saDNA-based vaccine candidates. This model is a first of its kind, promising rapid and reliable assessments of vaccine efficacy. Researchers from LSTM and iiDiagnostics, led by Professor Giancarlo Biagini and Dr. Shaun Pennington, will spearhead this innovative project.
Focus on SARS-CoV-2 and Beyond
The initial phase of research will focus on Eyam’s universal SARS-CoV-2 vaccine candidate, which utilizes the proprietary Jennerator AI engine for design and the Gemini saDNA platform for delivery. Additionally, the project will explore the Gemini platform’s ability to deliver multiple antigens from a single dose. This advancement could lead to vaccines that provide broader protection against various respiratory viruses and other global health threats.
Strategic Collaboration for Innovation
This cross-border partnership not only aims to generate valuable translational data but also seeks to establish new industry access models for the Liverpool Robotic Infection Research Laboratory. Insights gained from this collaboration will inform the long-term commercialization strategies of iiCON concerning automated human organoid systems, benefiting pharmaceutical and biotech partners.
Statements from Leadership
Ryan Thomas, CEO of Eyam Health, expressed the transformative potential of this collaboration, highlighting the ability to test and validate their platforms in a human-relevant model under high-containment conditions. He emphasized the goal of creating a new framework for vaccine development that prioritizes speed, scalability, and precision without reliance on outdated testing methods.
Professor Janet Hemingway, Founding Director of iiCON, noted the partnership’s significance in demonstrating the capabilities of the Liverpool Robotic Infection Research Laboratory to support innovative companies. She recognized that the project will contribute not only to the advancement of vaccine candidates but also to the development of commercially viable services within the broader biotech landscape.
A New Era in Vaccine Development
This collaboration marks a pivotal moment in vaccine research and development, showcasing the potential of automated and human-relevant testing methodologies. By accelerating candidate screening and yielding more predictive data than traditional in vivo models, the partnership is set to redefine the future of vaccine development and enhance pandemic preparedness.
Strengthening Bilateral Relations
The initiative also reinforces the cooperation between UK and Canadian institutions, aligning both nations’ efforts toward enhanced biosecurity and global health resilience. As the world continues to face emerging infectious diseases, partnerships like this are essential in building robust responses and ensuring health security on a global scale.
Founded in 2020, Eyam Health is dedicated to advancing biologics through innovative technologies such as its self-amplifying DNA delivery system and AI design engine. The company’s work spans various health domains, including infectious diseases and oncology, aiming to create more effective and accessible therapeutic solutions.
Conclusion
The collaboration between Eyam Health and iiDiagnostics is set to revolutionize the landscape of vaccine development. Through innovative technologies and strategic partnerships, this initiative not only promises to advance vaccine candidates but also contributes significantly to global health preparedness. As this partnership unfolds, it could serve as a model for future collaborations aimed at addressing the pressing challenges posed by infectious diseases.
- Key Takeaways:
- Eyam Health and iiDiagnostics unite to enhance vaccine technology.
- The partnership utilizes advanced automated organoid models for testing.
- Funding from multiple sources strengthens the project’s viability.
- The initiative aims to create broad-spectrum vaccines for global health threats.
- Collaboration enhances UK-Canada relations in biosecurity efforts.
Read more → www.palmbeachpost.com